Hypertriglyceridaemia: Aetiology, complications and management

References

• Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999; 99(22): 2852–4.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol 1999; 22(6 Suppl): N15–N20.
   PubMed Web of Science ®Google Scholar
• Wang J, Cao H, Ban MR, et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 2007; 27(11): 2450–5.
   PubMed Web of Science ®Google Scholar
• Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276(1): 34–42.
   PubMed Web of Science ®Google Scholar
• Pouwels ED, Blom DJ, Firth JC, Henderson HE, Marais AD. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience. S Afr Med J 2008; 98(2): 105–8.
   PubMed Web of Science ®Google Scholar
• Fojo SS, Baggio G, Gabelli C, et al. Apolipoprotein C-II deficiency: identification of a structural variant ApoC-II Padova. Biochem Biophys Res Commun 1988; 154(1): 73–79.
   PubMed Web of Science ®Google Scholar
• Fojo SS, Lohse P, Parrott C, et al. A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency. J Clin Invest 1989; 84(4): 1215–9.
   PubMed Web of Science ®Google Scholar
• Fojo SS, de Gennes JL, Beisiegel U, et al. Molecular genetics of apoC-II and lipoprotein lipase deficiency. Adv Exp Med Biol 1991; 285: 329–33.
   PubMedGoogle Scholar
• Beil FU, Fojo SS, Brewer HB, Jr, Greten H, Beisiegel U. Apolipoprotein C-II deficiency syndrome due to apo C-IIHamburg: clinical and biochemical features and HphI restriction enzyme polymorphism. Eur J Clin Invest 1992; 22(2): 88–95.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Huang Y, Rall SC, Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999; 40(11): 1933–49.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia—clinical and pathophysiological features. S Afr Med J 2002; 92(11): 892–7.
   PubMed Web of Science ®Google Scholar
• Hegele RA. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001; 69(6): 1161–77.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Pollex RL. Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem 2009; 326(1–2): 35–43.
   PubMed Web of Science ®Google Scholar
• Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73(4): 259–64.
   PubMed Web of Science ®Google Scholar
• Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009; 20(6): 497–504.
   PubMed Web of Science ®Google Scholar
• Sharma P, Lim S, James D, Orchard RT, Horne M, Seymour CA. Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia. BMJ 1996; 313(7067): 1265.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Kimura S, Fujimoto K, et al. A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. Ther Apher Dial 2008; 12(6): 509–13.
   PubMed Web of Science ®Google Scholar
• Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10(15): 2272–4.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77(14): 1179–84.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992; 70(19): 10H–13H.
   Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2): 213–9.
   PubMedGoogle Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298(3): 309–16.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54(1): 11–13.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341(6): 410–8.
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260(5): 641–51.
   PubMed Web of Science ®Google Scholar
• Yuan G, Al Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176(8): 1113–20.
   PubMed Web of Science ®Google Scholar
• Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007; 357(10): 1009–17.
   PubMed Web of Science ®Google Scholar
• Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009; 121(6): 148–57.
   PubMed Web of Science ®Google Scholar
• Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med 2009; 121(4): 145–53.
   PubMed Web of Science ®Google Scholar
• Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92(3): 536–41.
   PubMed Web of Science ®Google Scholar
• Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15(12): 1993–9.
   PubMed Web of Science ®Google Scholar
• Sood A, Arora R. Mechanisms of flushing due to niacin and abolition of these effects. J Clin Hypertens (Greenwich) 2009; 11(11): 685–9.
   PubMed Web of Science ®Google Scholar